Blueprint Medicines Q2 2021 Earnings Report
Key Takeaways
Blueprint Medicines reported a revenue of $27.3 million for the second quarter of 2021, including $8.5 million from AYVAKIT/AYVAKYT and $2.9 million from GAVRETO. The company's net loss was $108.4 million, or $1.86 per share. They also initiated multiple clinical trials and announced a research collaboration with MD Anderson.
Secured U.S. approval of AYVAKIT for advanced systemic mastocytosis and launched the therapy.
AYVAKIT/AYVAKYT generated $8.5 million in net product revenue.
GAVRETO recorded $2.9 million in net product revenue.
Initiated Phase 1/2 trial of BLU-945 and Phase 2/3 HARBOR trial of BLU-263.
Blueprint Medicines
Blueprint Medicines
Forward Guidance
Blueprint Medicines expects to present preclinical data for BLU-945 and BLU-701 in 2H 2021, initiate Phase 1 trials for BLU-701 in 2H 2021 and BLU-222 in 1H 2022, and disclose topline data for AYVAKIT's PIONEER trial in mid-2022.
Positive Outlook
- Present preclinical data supporting combination of BLU-945 and BLU-701 in treatment-naïve EGFR-driven NSCLC in the second half of 2021.
- Initiate a Phase 1 trial of BLU-701 in patients with treatment-resistant EGFR-driven NSCLC in the second half of 2021.
- Initiate a Phase 1 trial of BLU-222, a CDK2 inhibitor targeting cyclin-E aberrant cancers, in the first half of 2022.
- Disclose topline data for the registration-enabling Part 2 of the PIONEER trial of AYVAKIT in non-advanced systemic mastocytosis in mid-2022.